To identify and address specific oncology outcomes research issues and to develop recommendations to address these issues.


The field of oncology outcomes research is complicated by the diversity of diseases within oncology, the rapidly changing nature of treatments, and the complexities of measuring cost, and quality of life - patient reported outcomes. As such, oncology outcomes research constitutes a unique segment of outcomes research, one that requires specific clinical and methodological knowledge for its proper conduct.



Haitham Tuffaha, MSc, MBA, RPh, PhD, BSc

Health Technology Assessment Leader, University of Queensland, Centre for the Business and Economics of Health
Brisbane, QLD, Australia


Sang Kyu Cho, PharmD, MPH

Associate, Analysis Group
Boston, MA, United States

Working Groups

Member Engagement


Abeer Al Rabayah, MSc, MBA, BSc

Head, Center for Drug Policy & Technology Assessment, King Hussein Cancer Center
Amman, Jordan

Dem Aliaj, MSc

MSc, University of Lucerne
Kriens, LU, Switzerland

Brittany Carson, PhD, MHEcon, BSc

Medical Director, ApotheCom
New York, NY, United States

Kathryn Chung

AD Market Access, MSD
Singapore, 01, Singapore

Shay Ganesh

Health, Abhi
Thane, India

Christopher Graham, MS, BS

Senior Director, Health Economics, RTI Health Solutions
Durham, NC, United States

Min-Hua Jen, PhD

Director, Eli Lilly
Uxbridge, LON, United Kingdom

Sorrel Wolowacz, PhD

Head, EU Health Economics, RTI Health Solutions
Manchester, United Kingdom

Questions or ideas? Please send an email to Oncologysig@ISPOR.org

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now